Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus Docetaxel in Advanced Non-squamous NSCLC With Bone Metastases
NCT03127319Phase 2Unknown
- Sponsor
- Affiliated Hospital of Hebei University
- Start
- Jul 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Rivoceranib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Affiliated Hospital of Hebei University. Primary endpoint: Progression-Free Survival at 6 weeks. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03127319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127319.